Literature DB >> 16036421

Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum?

Michael J Strong1, Paul H Gordon.   

Abstract

Among the motor neuron diseases, three share the clinical features of prominent upper motor neuron signs--amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) and the hereditary spastic paraplegias (HSP). While genetic testing can assist in the identification of several variants of the latter, in the remaining cases, including those in which spasticity may be associated with amyotrophy, clinical differentiation of the three disorders may prove difficult. In this paper we review the evidence that these are distinct disorders and conclude that, for ALS and PLS particularly, there may be justification in considering them as single points along a continuum of multisystem disorders with conspicuous motor neuron involvement. Only through the development and application of exacting clinical diagnostic criteria to epidemiological studies, along with greater numbers of post-mortem examinations, however, will these questions be answered fully.

Entities:  

Mesh:

Year:  2005        PMID: 16036421     DOI: 10.1080/14660820410021267

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  17 in total

1.  [Provision of assistive devices in amyotrophic lateral sclerosis. Analysis of 3 years case management in an internet-based supply network].

Authors:  A Funke; T Grehl; J Großkreutz; C Münch; B Walter; D Kettemann; C Karnapp; N Gajewski; R Meyer; A Maier; K M Gruhn; T Prell; K Kollewe; S Abdulla; X Kobeleva; S Körner; S Petri; T Meyer
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

2.  Hypercapnia is a possible determinant of the function of the blood-cerebrospinal fluid barrier in amyotrophic lateral sclerosis.

Authors:  Sigurd D Süssmuth; Anne D Sperfeld; Albert C Ludolph; Hayrettin Tumani
Journal:  Neurochem Res       Date:  2010-03-24       Impact factor: 3.996

3.  Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD).

Authors:  Emanuele D'Amico; Meredith Pasmantier; Yei-Won Lee; Louis Weimer; Hiroshi Mitsumoto
Journal:  Muscle Nerve       Date:  2012-11-21       Impact factor: 3.217

Review 4.  The frontotemporal syndromes of ALS. Clinicopathological correlates.

Authors:  Michael Joseph Strong; Wencheng Yang
Journal:  J Mol Neurosci       Date:  2011-08-02       Impact factor: 3.444

5.  SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis.

Authors:  Antonio Orlacchio; Carla Babalini; Antonella Borreca; Clarice Patrono; Roberto Massa; Sarenur Basaran; Renato P Munhoz; Ekaterina A Rogaeva; Peter H St George-Hyslop; Giorgio Bernardi; Toshitaka Kawarai
Journal:  Brain       Date:  2010-01-28       Impact factor: 13.501

Review 6.  Molecular logic of neocortical projection neuron specification, development and diversity.

Authors:  L C Greig; M B Woodworth; M J Galazo; H Padmanabhan; J D Macklis
Journal:  Nat Rev Neurosci       Date:  2013-10-09       Impact factor: 34.870

Review 7.  Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene.

Authors:  Peter M Andersen
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

8.  Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET.

Authors:  Martin R Turner; Alexander Hammers; Ammar Al-Chalabi; Christopher E Shaw; Peter M Andersen; David J Brooks; P Nigel Leigh
Journal:  J Neurol       Date:  2007-02-09       Impact factor: 4.849

9.  Altered gene expression, mitochondrial damage and oxidative stress: converging routes in motor neuron degeneration.

Authors:  Luisa Rossi; Cristiana Valle; Maria Teresa Carrì
Journal:  Int J Cell Biol       Date:  2012-05-17

10.  Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application.

Authors:  Chen Benkler; Daniel Offen; Eldad Melamed; Lana Kupershmidt; Tamar Amit; Silvia Mandel; Moussa B H Youdim; Orly Weinreb
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.